Jes Besharah
YOU?
Author Swipe
View article: Initiation of opioid agonist treatment following hospital-treated opioid toxicities and the risk of repeat events in Ontario, Canada: a cohort study using inverse probability of treatment weights
Initiation of opioid agonist treatment following hospital-treated opioid toxicities and the risk of repeat events in Ontario, Canada: a cohort study using inverse probability of treatment weights Open
Introduction The period following hospital discharge for opioid toxicity presents an increased risk for repeat events. While opioid agonist treatment (OAT) can reduce this risk, in-hospital initiation rates remain low, and the impact of ea…
View article: Pathways of care following opioid overdose among people with opioid use disorder: A multilevel cohort study
Pathways of care following opioid overdose among people with opioid use disorder: A multilevel cohort study Open
The identification of factors associated with treatment initiation following overdose may be associated with promoting longer stays in hospital and enhancing accessibility in regions with less experience managing opioid overdoses.
View article: Trends in opioid toxicities among people with and without opioid use disorder and the impact of the COVID-19 pandemic in Ontario, Canada: A population-based analysis
Trends in opioid toxicities among people with and without opioid use disorder and the impact of the COVID-19 pandemic in Ontario, Canada: A population-based analysis Open
The rate of opioid toxicities accelerated across Ontario following the pandemic-related state of emergency, with the majority of this increase among people with OUD. The important differences observed among people with OUD compared with th…
View article: Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada
Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada Open
On average, people initiating BUP-ER discontinue within the first 6 months of treatment. While BUP-ER is likely providing an important OAT option, the high occurrence of discontinuation, supplementation with buprenorphine/naloxone, and fre…